Cancer Hospital of Huanxing Chaoyang District Beijing
- Research works
- 110 ▲ 268% vs 2013–17
- Citations
- 869 7.9 per fractional work
- Top-10% rate
- 9.8% record average 16.5%
- Open access
- 63% world 28%
Not ranked overall: Cancer Hospital of Huanxing Chaoyang District Beijing is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
What does Cancer Hospital of Huanxing Chaoyang District Beijing specialise in?
Where its research is concentrated relative to its size: Medicine takes 4.0× the share of its output that it takes of world research.
- MedicineField · 44.6 works4.0×
- Health SciencesDomain · 45.8 works3.5×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Medicine, 4.0×. Every wedge is a field page.
- Medicine 4.0×
- Biochemistry, Genetics and Molecular Biology 2.2×
- Immunology and Microbiology 2.2×
- Health Professions 0.7×
- Nursing 0.3×
- Economics, Econometrics and Finance 0.3×
- Pharmacology, Toxicology and Pharmaceutics 0.3×
- Chemistry 0.3×
- Materials Science 0.2×
- Engineering 0.2×
- Neuroscience 0.1×
- Social Sciences 0.1×
- Computer Science 0.0×
- Environmental Science 0.0×
Which keywords describe research at Cancer Hospital of Huanxing Chaoyang District Beijing?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Chemotherapy, Tumor Microenvironment, Immunotherapy, Breast Cancer, Clinical Practice Guidelines, Neoadjuvant Therapy, Targeted Therapy and Metastatic Breast Cancer.
- Photodynamic Therapy
- Fluorouracil
- Genetic Mutations
- CDK4/6 Inhibitors
- Gastric Cancer
- BRAF Mutation
- Genomic Profiling
- HER2
- Trastuzumab
- Endoscopic Resection
- Adjuvant Therapy
- Prognostic Factors
- Molecular Characterization
- Radiotherapy
- Immune Checkpoint Blockade
- Clinical Trials
- Targeted Therapy
- Neoadjuvant Therapy
- Breast Cancer
- Tumor Microenvironment
- Chemotherapy
- Immunotherapy
- Clinical Practice Guidelines
- Quality of Life
- Metastatic Breast Cancer
- Survival Analysis
- PD-1 and PD-L1
- Cancer
- Molecular Subtypes
- Metastatic
- Biomarkers
- Gene Expression
- EGFR
- Metastasis
- Precision Medicine
- Cetuximab
- Tumor Markers
- Palbociclib
- Reactive Oxygen Species
- KRAS Mutations
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Chemotherapy14▲ 35×18 topics
- Tumor Microenvironment7▲ 28×7 topics
- Immunotherapy7▲ 17×9 topics
- Breast Cancer6▲ 41×7 topics
- Clinical Practice Guidelines5▲ 17×6 topics
- Neoadjuvant Therapy5▲ 40×5 topics
- Quality of Life4▲ 5.2×7 topics
- Targeted Therapy4▲ 33×4 topics
- Metastatic Breast Cancer4▲ 126×2 topics
- Clinical Trials4▲ 11×4 topics
- Survival Analysis4▲ 26×4 topics
- Immune Checkpoint Blockade4▲ 57×1 topic
- PD-1 and PD-L14▲ 57×1 topic
- Radiotherapy3▲ 15×6 topics
- Cancer3▲ 4.4×18 topics
- Molecular Characterization3▲ 32×4 topics
- Molecular Subtypes3▲ 66×2 topics
- Prognostic Factors3▲ 13×7 topics
- Metastatic3▲ 86×2 topics
- Adjuvant Therapy3▲ 40×2 topics
- Biomarkers3▲ 7.3×6 topics
- Endoscopic Resection3▲ 49×2 topics
- Gene Expression3▲ 7.6×4 topics
- Trastuzumab3▲ 101×2 topics
- EGFR2▲ 153×1 topic
- HER22▲ 153×1 topic
- Metastasis2▲ 13×6 topics
- Genomic Profiling2▲ 41×2 topics
- Precision Medicine2▲ 9.1×5 topics
- BRAF Mutation2▲ 57×2 topics
- Cetuximab2▲ 48×2 topics
- Gastric Cancer2▲ 35×2 topics
- Tumor Markers2▲ 49×2 topics
- CDK4/6 Inhibitors2▲ 155×1 topic
- Palbociclib2▲ 155×1 topic
- Genetic Mutations2▲ 8.5×4 topics
- Reactive Oxygen Species2▲ 9.3×4 topics
- Fluorouracil2▲ 106×1 topic
- KRAS Mutations2▲ 106×1 topic
- Photodynamic Therapy2▲ 16×2 topics
Which research topics does Cancer Hospital of Huanxing Chaoyang District Beijing publish most on?
By volume in 2022–2025: Cancer Immunotherapy and Biomarkers, HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies and Colorectal Cancer Treatments and Studies.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Cancer Immunotherapy and Biomarkers Oncology 4 works
- 2 HER2/EGFR in Cancer Research Oncology 2 works
- 3 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 2 works
- 4 Colorectal Cancer Treatments and Studies Oncology 2 works
- 5 Cancer Treatment and Pharmacology Oncology 2 works
- 6 Gastric Cancer Management and Outcomes Pulmonary and Respiratory Medicine 2 works
- 7 Cancer survivorship and care Oncology 2 works
- 8 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 2 works
- 9 Lung Cancer Research Studies Oncology 2 works
- 10 Nanoplatforms for cancer theranostics Biomedical Engineering 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Cancer Hospital of Huanxing Chaoyang District Beijing's research output changed?
Output in 2018–2022 was 268% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Beijing
- Chinese Academy of Sciences
- Tsinghua University
- Peking University
- University of Chinese Academy of Sciences
- Beihang University
- Beijing Institute of Technology
- Chinese Academy of Medical Sciences & Peking Union Medical College
- North China Electric Power University
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.